The company is investing DKK1.5bn ($223m) in this new facility, which is designed to produce active pharmaceutical ingredients for NovoSeven and future products to treat haemophilia.
With the investment, 100 new production and engineering jobs will be created in Kalundborg, where the company currently employs more than 2,800 people.
Novo Nordisk Product Supply executive vice-president Henrik Wulff said: "The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark.
"This year alone we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly skilled employees."
The new manufacturing facility is expected to be approved and fully operational in 2020.
Haemophilia is a bleeding disorder and people with it have either decreased, defective or absent production of blood clotting protein.
For people with haemophilia, bleeds often occur in the joints, particularly knees and ankles, while they can also occur in the muscles, soft tissues, gastrointestinal tract or even the brain.
Image: Novo Nordisk’s new haemophilia treatment manufacturing facility will be fully operational in 2020. Photo: courtesy of Baitong333/ FreeDigitalPhotos.net.